Embecta Corp.

  • Earnings Score
  • Safety Score
  • Market Cap $705.28M
  • Debt $1.58B
  • Cash $216.70M
  • EV $2.07B
  • FCF $28.90M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings$58.20M
EBIT$150.00M
ROA13%
FCF$28.90M
Equity-$768.80M
Growth Stability20%
PE12.12
PEG-0.24
PB-0.92
P/FCF24.4
P/S0.64
Price/Cash0.31
Debt/Equity-2.05
Debt/FCF54.62
Net Margins0%
Gross Margins64%
Op. Margins14%
Earnings CAGR-50%
Sales Growth YoY-6%
Sales Growth QoQ-8%
Sales CAGR-1%
FCF CAGR-70%
Equity CAGR-0%
Earnings Stability-0.03
Earnings Growth YoY-100%
Earnings Growth QoQ-100%
Earnings CAGR 5Y-50%
Sales CAGR 5Y-1%
FCF CAGR 5Y-70%
Equity CAGR 5Y-0%
Earnings CAGR 3Y-1%
Sales CAGR 3Y-1%
FCF CAGR 3Y-76%
Market Cap$705.28M
Revenue$1.11B
Dividend Yield5%
Payout Ratio60%
Assets$1.15B
Total Debt$1.58B
Cash$216.70M
Shares Outstanding57.95M
EV2.07B
Earnings Score6%
Safety Score15%
Working Capital369M
Current Ratio2.24
Gross Profit$706.40M
Shares Growth 3y0%
Equity Growth QoQ4%
Equity Growth YoY-3%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Embecta Corp is a medical technology company. The company develops innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for healthcare providers. Its products include BD Pyxis, PureWick, Phasix among others.

SEC Filings

Direct access to Embecta Corp. (EMBC) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Dec 31
    • 10-K Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-Q Dec 31
    • 10-K Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-Q Dec 31
    • 10-K Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Embecta Corp. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Embecta Corp. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -50%
Stability -3%
loading chart...

Embecta Corp. Discounted Cash Flow

Fully customizable DCF calculator online for Embecta Corp..

= $11M
012345678910TV
fcf$29M$8.7M$2.6M$784K$235K$71K$21K$6.4K$1.9K$576$173$1.7K
DCF$7.9M$2.2M$589K$161K$44K$12K$3.3K$895$244$67$667
Value$11M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years09/202009/202109/202209/202309/2024TTM
Net Margins39%36%20%6%7%0%
ROA-63%28%18%13%13%
ROE-70%-25%-9%-11%-

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years09/202009/202109/202209/202309/2024TTM
Debt over FCF-04.2639.9380.9454.62
Debt over Equity00-1.86-2-2.18-2.05
Growth Stability---20%33%20%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years09/202009/202109/202209/202309/2024CAGR 5Y
Revenue YoY growth-7%-3%-1%0%-1%
Earnings YoY growth--3%-46%-69%11%-50%
Equity YoY growth-4%-250%-8%-10%-0%
FCF YoY growth--8%-7%-89%-52%-70%